Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ENTADFI vs JALYN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of a 5α-reductase inhibitor (finasteride) and a phosphodiesterase 5 inhibitor (tadalafil). Finasteride inhibits type II 5α-reductase, preventing conversion of testosterone to dihydrotestosterone, reducing prostate growth. Tadalafil inhibits PDE5, increasing c GMP in smooth muscle, causing relaxation of the prostate and bladder neck.
Jalyn is a combination of dutasteride, a 5α-reductase inhibitor that inhibits the conversion of testosterone to dihydrotestosterone (DHT), and tamsulosin, an α1-adrenoceptor antagonist that relaxes smooth muscle in the prostate and bladder neck.
Treatment of signs and symptoms of benign prostatic hyperplasia (BPH),Treatment of BPH in men with an enlarged prostate to improve symptoms, reduce risk of acute urinary retention, and reduce need for surgery
Treatment of symptomatic benign prostatic hyperplasia (BPH),Reduction in risk of acute urinary retention,Reduction in risk of need for BPH-related surgery
5 mg orally once daily.
1 capsule (0.5 mg dutasteride/0.4 mg tamsulosin) orally once daily, 30 minutes after the same meal each day.
Finasteride: terminal half-life ~6-8 hours (range 4-12 h) in young adults, 8 hours in elderly. Tadalafil: terminal half-life ~17.5 hours (range 11-28 h), supporting once-daily dosing.
Dutasteride: 5 weeks (t½ ∼3-5 weeks) due to high tissue binding and slow elimination; Tamsulosin: 9-13 hours (t½ ∼9-13 h) in healthy subjects, prolonged in elderly (∼14-15 h).
Finasteride is metabolized primarily via CYP3A4. Tadalafil is metabolized mainly by CYP3A4.
Dutasteride is extensively metabolized by CYP3A4 and CYP3A5. Tamsulosin is extensively metabolized by CYP3A4 and CYP2D6.
ENTADFI (finasteride 5 mg and tadalafil 5 mg) is a fixed-dose combination. Finasteride is excreted 57% in feces (as metabolites) and 39% in urine (<1% as unchanged). Tadalafil is excreted primarily as metabolites, with 61% in feces and 36% in urine; <0.001% of dose is excreted unchanged in urine.
Dutasteride: 40% renal, 60% fecal as metabolites; Tamsulosin: 76% renal (9% unchanged), 24% fecal as metabolites.
Finasteride: ~90% bound to plasma proteins (mainly albumin). Tadalafil: ~94% bound to plasma proteins (mainly albumin).
Dutasteride: 99.0-99.5% bound to albumin and alpha-1-acid glycoprotein; Tamsulosin: 94-99% bound to alpha-1-acid glycoprotein.
Finasteride: Vd ≈ 76 L (approx 1.1 L/kg based on 70 kg). Tadalafil: Vd ≈ 63-77 L (approx 0.9-1.1 L/kg), indicating extensive tissue distribution.
Dutasteride: 300-500 L (∼3-4 L/kg); Tamsulosin: 16 L (∼0.2 L/kg). Dutasteride’s large Vd indicates extensive tissue distribution.
Finasteride 5 mg: oral bioavailability ~63% (range 56-74%). Tadalafil 5 mg: oral bioavailability ~80% (relative to intravenous); absorption not affected by food.
Oral: Dutasteride ∼60% (capsule); Tamsulosin ∼90% (capsule, under fed conditions slightly reduced).
No dose adjustment required for mild to moderate renal impairment. Not recommended in severe renal impairment (e GFR <30 m L/min/1.73 m²).
No dose adjustment required for mild to moderate renal impairment (GFR ≥30 m L/min). Not recommended for severe renal impairment (GFR <30 m L/min) due to lack of data.
Contraindicated in Child-Pugh class B and C hepatic impairment. No dose adjustment required for Child-Pugh class A.
Contraindicated in severe hepatic impairment (Child-Pugh class C). No dose adjustment for mild to moderate impairment (Child-Pugh A or B), but use with caution.
Not approved for use in pediatric patients.
Not indicated for use in pediatric patients. Safety and efficacy not established.
No specific dose adjustment required; however, monitor for adverse effects due to potential age-related renal and hepatic decline.
No specific dose adjustment recommended based on age alone. Monitor for orthostatic hypotension, dizziness, and falls risk, especially in elderly patients. Consider underlying renal and hepatic function.
No FDA black box warning.
None.
Hypersensitivity reactions,Sudden decrease in hearing or tinnitus,Prostate cancer screening and monitoring,Cardiovascular risk with sexual activity,Contraindicated with organic nitrates and GC stimulators (e.g., riociguat),Risk of priapism,Hepatic impairment dose adjustment,Renal impairment dose adjustment,Use of alpha-blockers,Antihypertensive effects,Risk of hypotension with concomitant alcohol
Use with caution in combination with other alpha-blockers due to risk of hypotension,Postural hypotension may occur, especially at initiation of therapy,Not recommended for use in women, children, or adolescents due to teratogenic risk,Evaluate for prostate cancer before initiating therapy,Dutasteride may increase risk of high-grade prostate cancer in some studies,Hepatic impairment may alter metabolism of dutasteride
Hypersensitivity to finasteride, tadalafil, or any component,Concurrent use of any organic nitrate,Concurrent use of guanylate cyclase stimulators (e.g., riociguat),Women, especially during pregnancy (finasteride teratogenicity)
Hypersensitivity to dutasteride, tamsulosin, or any component of the formulation,Use in women of childbearing potential,Use in pediatric patients
Grapefruit juice may increase tadalafil plasma concentrations; avoid concurrent consumption. High-fat meals may delay tadalafil absorption but do not affect overall exposure. There are no significant food interactions with finasteride.
Avoid grapefruit juice; may increase tamsulosin exposure and adverse effects. Administer with a meal (same meal consistency daily) to reduce tamsulosin-related adverse events. No other food interactions known.
ENTADFI (finasteride and tadalafil) is contraindicated in pregnancy. Finasteride is a 5α-reductase inhibitor that inhibits conversion of testosterone to dihydrotestosterone (DHT) and can cause abnormal development of external genitalia in male fetuses. First trimester exposure is associated with hypospadias and other genital malformations. There is no human data for second and third trimester; however, based on mechanism, risks persist throughout pregnancy. Tadalafil, a PDE5 inhibitor, is Pregnancy Category B; no fetal harm is known in animals, but human data are limited.
JALYN (dutasteride/tamsulosin) is contraindicated in pregnancy. Dutasteride is a 5-alpha-reductase inhibitor that can inhibit dihydrotestosterone formation, potentially causing abnormal development of external genitalia in male fetuses. Tamsulosin is an alpha-1 blocker with limited data but potential risks. First trimester: avoid; second and third trimesters: avoid due to theoretical risk.
No data available on ENTADFI (finasteride/tadalafil) in human milk. Finasteride is excreted in rat milk, but M/P ratio is unknown. Tadalafil is excreted in animal milk; M/P ratio unknown. Due to potential for adverse effects on lactating infant, especially from finasteride (possible interference with androgen metabolism), breastfeeding is not recommended during treatment and for at least 1 month after last dose.
JALYN is not indicated for use in women. Dutasteride and tamsulosin are excreted in rat milk but no human data. M/P ratio unknown; avoid breastfeeding due to potential adverse effects in infants.
ENTADFI is contraindicated in pregnancy; no dosing adjustments are recommended because use is not permitted. If inadvertently administered, discontinue immediately. There are no established pharmacokinetic changes in pregnancy for finasteride or tadalafil; however, pregnancy-induced changes in drug metabolism are not expected to alter the need for dose adjustment because the drug is not used during gestation.
No dose adjustments are applicable because JALYN is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy are irrelevant as the drug should not be used.
ENTADFI (finasteride and tadalafil fixed-dose combination) is used for benign prostatic hyperplasia (BPH). Finasteride reduces DHT, improving symptoms and reducing risk of acute urinary retention; tadalafil enhances smooth muscle relaxation via PDE5 inhibition. Monitor PSA levels during therapy (finasteride halves PSA). Assess cardiovascular status before initiating tadalafil; avoid concurrent nitrates. Caution in hepatic impairment (tadalafil exposure increased). Advise patients that therapeutic effect may take 3-6 months.
Jalyn is a fixed-dose combination of dutasteride (5α-reductase inhibitor) and tamsulosin (α1-adrenergic antagonist) for symptomatic benign prostatic hyperplasia (BPH). Onset of symptom relief is faster than either agent alone. Tamsulosin component may cause orthostatic hypotension, especially in elderly patients; counsel to rise slowly. Dutasteride reduces serum prostate-specific antigen (PSA) by approximately 50% after 6 months; PSA levels should be interpreted accordingly. Avoid use in women of childbearing potential; dutasteride is teratogenic and can be absorbed through skin contact with capsules.
Take ENTADFI at the same time daily with or without food.,Do not take more than one dose per day.,Avoid grapefruit juice as it may increase tadalafil levels.,Report sudden decrease in hearing or vision promptly.,Seek immediate medical help for erection lasting >4 hours.,Use contraception if partner is pregnant or may become pregnant (finasteride can cause fetal harm).,Do not donate blood during treatment and for 1 month after stopping.,Avoid alcohol excessively as it may increase risk of hypotension.
Take Jalyn 30 minutes after the same meal each day to maintain consistent absorption.,Do not crush, chew, or open capsules; swallow whole.,Avoid grapefruit juice, which may increase tamsulosin levels.,Rise slowly from sitting or lying to prevent dizziness from low blood pressure.,Report symptoms like fainting, severe headache, or prolonged painful erection (priapism) immediately.,Do not donate blood during therapy and for 6 months after stopping due to dutasteride transfer risk.,Use reliable contraception if partner is of childbearing potential; dutasteride can cause fetal harm.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ENTADFI vs JALYN, answered by our medical review team.
ENTADFI is a 5-Alpha Reductase Inhibitor and PDE5 Inhibitor that works by Combination of a 5α-reductase inhibitor (finasteride) and a phosphodiesterase 5 inhibitor (tadalafil). Finasteride inhibits type II 5α-reductase, preventing conversion of testosterone to dihydrotestosterone, reducing prostate growth. Tadalafil inhibits PDE5, increasing c GMP in smooth muscle, causing relaxation of the prostate and bladder neck.. JALYN is a 5-Alpha Reductase Inhibitor/Alpha-1 Blocker Combination that works by Jalyn is a combination of dutasteride, a 5α-reductase inhibitor that inhibits the conversion of testosterone to dihydrotestosterone (DHT), and tamsulosin, an α1-adrenoceptor antagonist that relaxes smooth muscle in the prostate and bladder neck.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ENTADFI and JALYN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ENTADFI is: 5 mg orally once daily.. The standard adult dose of JALYN is: 1 capsule (0.5 mg dutasteride/0.4 mg tamsulosin) orally once daily, 30 minutes after the same meal each day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ENTADFI and JALYN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ENTADFI is classified as Category C. ENTADFI (finasteride and tadalafil) is contraindicated in pregnancy. Finasteride is a 5α-reductase inhibitor that inhibits conversion of testosterone to dihydrotestosterone (DHT) a. JALYN is classified as Category C. JALYN (dutasteride/tamsulosin) is contraindicated in pregnancy. Dutasteride is a 5-alpha-reductase inhibitor that can inhibit dihydrotestosterone formation, potentially causing abn. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.